Clinical Trial

A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of [225Ac]Ac-PSMA-XT Injection in Patients With Metastatic Castration-resistant Prostate Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the safety and efficacy of 225Ac -labeled PSMA ligand(PSMA-XT) in the treatment of mCRPC
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-14.
Trial Details
NCT Number NCT07135102
Lead Sponsor Xiaorong Sun
Conditions Metastatic Castration-Resistant Prostate Cancer Patients
Enrollment 40 participants
Start Date 2024-10-14
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-24